StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ - Free Report) in a research report report published on Saturday. The brokerage issued a hold rating on the medical research company's stock.
Enzo Biochem Price Performance
NYSE:ENZ opened at $0.98 on Friday. The firm has a 50-day moving average of $1.12 and a 200-day moving average of $1.12. Enzo Biochem has a one year low of $0.93 and a one year high of $1.50.
Enzo Biochem Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 15th will be given a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a yield of 40.82%. The ex-dividend date is Friday, November 15th.
Institutional Investors Weigh In On Enzo Biochem
Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd grew its position in Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock worth $31,000 after purchasing an additional 13,735 shares in the last quarter. BBR Partners LLC purchased a new position in Enzo Biochem in the third quarter valued at about $112,000. Geode Capital Management LLC boosted its stake in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company's stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock valued at $2,725,000 after acquiring an additional 64,417 shares during the last quarter. 36.90% of the stock is owned by institutional investors.
About Enzo Biochem
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
